UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 280

Sortiert nach

Systemic amyloidosis from A (AA) to T (ATTR): a review

Journal of internal medicine, 2021-03, Vol.289 (3), p.268-292

2021

Volltextzugriff (PDF)

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Leukemia, 2014-05, Vol.28 (5), p.1122-1128

2014

Volltextzugriff (PDF)

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

Leukemia, 2017-12, Vol.31 (12), p.2791-2798

2017

Volltextzugriff (PDF)

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Leukemia, 2016-11, Vol.30 (11), p.2208-2213

2016

Volltextzugriff (PDF)

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis

Bone marrow transplantation (Basingstoke), 2013-04, Vol.48 (4), p.557-561

2013

Volltextzugriff (PDF)

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Leukemia, 2016-03, Vol.30 (3), p.633-639

2016

Volltextzugriff (PDF)

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

Leukemia, 2017-07, Vol.31 (7), p.1562-1569

2017

Volltextzugriff (PDF)

Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression

Leukemia, 2017-01, Vol.31 (1), p.130-135

2017

Volltextzugriff (PDF)

Natural history of t(11;14) multiple myeloma

Leukemia, 2018-01, Vol.32 (1), p.131-138

2018

Volltextzugriff (PDF)

"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience

Blood cancer journal (New York), 2021-12, Vol.11 (12), p.196-196, Article 196

2021

Volltextzugriff (PDF)

Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival

Bone marrow transplantation (Basingstoke), 2017-08, Vol.52 (8), p.1126-1132

2017

Volltextzugriff (PDF)

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Leukemia, 2024-08, Vol.38 (8), p.1866-1866

2024

Volltextzugriff (PDF)

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Leukemia, 2021-12, Vol.35 (12), p.3604-3607

2021

Volltextzugriff (PDF)

Autologous stem cell transplant for multiple myeloma patients 70 years or older

Bone marrow transplantation (Basingstoke), 2016-11, Vol.51 (11), p.1449-1455

2016

Volltextzugriff (PDF)

Second auto-SCT for treatment of relapsed multiple myeloma

Bone marrow transplantation (Basingstoke), 2013-04, Vol.48 (4), p.568-573

2013

Volltextzugriff (PDF)

Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

Cancer gene therapy, 2010-08, Vol.17 (8), p.550-558

2010

Volltextzugriff (PDF)

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

Blood cancer journal (New York), 2023-05, Vol.13 (1), p.91-91

2023

Volltextzugriff (PDF)

Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation

Leukemia, 2018-03, Vol.32 (3), p.712-718

2018

Volltextzugriff (PDF)

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Leukemia, 2018-03, Vol.32 (3), p.719-728

2018

Volltextzugriff (PDF)

Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis

Journal of internal medicine, 2017-06, Vol.281 (6), p.611-619

2017

Volltextzugriff (PDF)

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Leukemia, 2010-11, Vol.24 (11), p.1934-1939

2010

Volltextzugriff (PDF)

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Leukemia, 2007-03, Vol.21 (3), p.529-534

2007

Volltextzugriff (PDF)

Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention

Bone marrow transplantation (Basingstoke), 2011-07, Vol.46 (7), p.943-949

2011

Volltextzugriff (PDF)

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

Leukemia, 2017-01, Vol.31 (1), p.92-99

2017

Volltextzugriff (PDF)

The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents

Bone marrow transplantation (Basingstoke), 2017-01, Vol.52 (1), p.34-40

2017

Volltextzugriff (PDF)

1 – 25 von 280

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(243)
Mit Volltextzugriff
(270)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Systemic amyloidosis from A (AA) to T (ATTR): a review

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression

Natural history of t(11;14) multiple myeloma

"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience

Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Autologous stem cell transplant for multiple myeloma patients 70 years or older

Second auto-SCT for treatment of relapsed multiple myeloma

Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents

Suchergebnisse filtern